Cargando…
Factors XI and XII as Targets for New Anticoagulants
Compared with vitamin K antagonists, the direct oral anticoagulants (DOACs) are simpler to administer and are associated with less intracranial bleeding. Nonetheless, even with the DOACs, bleeding still occurs and many patients with atrial fibrillation fail to receive anticoagulant thromboprophylaxi...
Autores principales: | Weitz, Jeffrey I., Fredenburgh, James C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323386/ https://www.ncbi.nlm.nih.gov/pubmed/28286749 http://dx.doi.org/10.3389/fmed.2017.00019 |
Ejemplares similares
-
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism
por: Li, Tingting, et al.
Publicado: (2022) -
Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants
por: Weitz, Jeffrey I., et al.
Publicado: (2017) -
The new in anticoagulation: factor XI inhibitors
por: Muscente, Francesca, et al.
Publicado: (2023) -
A demonstration of factor XI contributing to hemostasis in the absence of factor XII
por: Mohammed, Bassem M., et al.
Publicado: (2022) -
Processing of Factor XII during Inflammatory Reactions
por: Jukema, Bernard Nico, et al.
Publicado: (2016)